Bavarian Nordic A/S (OTCMKTS:BVNRY) Sees Large Growth in Short Interest

Bavarian Nordic A/S (OTCMKTS:BVNRY) was the target of a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 8,600 shares, an increase of 109.8% from the December 31st total of 4,100 shares. Based on an average daily trading volume, of 27,900 shares, the short-interest ratio is currently 0.3 days.

Bavarian Nordic A/S Trading Up 2.9 %

Shares of OTCMKTS:BVNRY opened at $9.22 on Wednesday. Bavarian Nordic A/S has a 12-month low of $6.86 and a 12-month high of $14.60. The stock’s 50-day moving average price is $9.01 and its 200-day moving average price is $10.13. The stock has a market capitalization of $2.18 billion, a P/E ratio of 13.36 and a beta of 1.65.

About Bavarian Nordic A/S

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.